A new option for remission induction in acute myeloid leukaemia
- 12 January 2018
- journal article
- editorial
- Published by Elsevier BV in The Lancet Oncology
- Vol. 19 (2), 156-157
- https://doi.org/10.1016/s1470-2045(18)30012-3
Abstract
No abstract availableFunding Information
- Deutsche Forschungsgemeinschaft
- AstraZeneca
- Celgene
This publication has 10 references indexed in Scilit:
- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b studyThe Lancet Oncology, 2018
- TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic SyndromesThe New England Journal of Medicine, 2016
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous LeukemiaCancer Discovery, 2016
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 2016
- Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemiaLeukemia, 2015
- Acute Myeloid LeukemiaThe New England Journal of Medicine, 2015
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blastsBlood, 2015
- DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapyBMC Cancer, 2015
- Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomesThe Lancet, 2010
- Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemiaBlood, 1988